Home / Business and Economy / Capricor Exec Sells $732K in Stock Options
Capricor Exec Sells $732K in Stock Options
25 Jul
Summary
- Executive Karen Krasney sold $732,000 worth of Capricor stock.
- The transaction involved exercising stock options and immediate sale.
- Krasney's direct ownership decreased significantly post-transaction.
Karen Krasney, the Executive Vice President and General Counsel of Capricor Therapeutics, has completed a substantial stock transaction valued at approximately $732,000. This involved the exercise of 24,100 stock options, followed by an immediate sale of the acquired common shares.
This exercise-and-sell event, conducted under a 10b5-1 trading plan, resulted in a notable decrease in Krasney's direct share ownership. Her holdings were reduced by 44.10%, bringing her total direct shares to 30,547. Importantly, the transaction did not involve any indirect holdings through trusts or other entities.
Capricor Therapeutics operates as a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases, with a particular focus on Duchenne muscular dystrophy. Its pipeline includes promising cell and exosome-based treatments.
The structure of this transaction, executed as part of a predetermined plan, suggests it was not influenced by insider knowledge of the company's performance or future stock price movements. Such trades are commonly linked to executive compensation packages.
